C-Terminal VWF Variants in von Willebrand Disease: Functional Insights from the D4-C6 Domains
The RPTH Journal (Research and Practice in Thrombosis and Haemostasis) shared an insightful post on LinkedIn:
”A small panel of VWF variants were investigated for expression and function – and how they might cause Von Willebrand Disease.
Golzar Mobayen and team reveal that the D4 and C-domains of VWF might play a role!
Other Authors: Sammy El-Mansi, Alain Chion, Tom Nightingale, and Tom McKinnon.”
Read the full article here.
The ”Probing rare von Willebrand disease–causing mutations in the D4 and C-domains of von Willebrand factor” study published by Golzar Mobayen et al. in the RPTH Journal, sheds light on the possible roles of vWF C-terminal D4-C6 domains in development of VWD.
Von Willebrand disease (VWD) arises from quantitative or qualitative deficiencies in von Willebrand factor (VWF), with a broad spectrum of genetic variants contributing to disease pathology.
However, mutations within the C-terminal D4-C6 domains of VWF remain under-characterized.
The findings demonstrate that variants in this region can significantly impair VWF expression and function.
Furthermore, the phenotypic impact varies depending on zygosity, with distinct differences observed between homozygous and heterozygous states.
These insights underscore the importance of the VWF C-terminal domains in maintaining normal hemostatic function.
All the latest scientific advancements on bleeding disorders featured in Hemostasis Today.
-
Sep 9, 2025, 23:00Blood Podcast Alert: LSD1 Inhibitors in SCD, Ruxolitinib+Dex in HLH, Low VWF Insights
-
Sep 9, 2025, 15:47AFib: A Hidden Stroke Risk
-
Sep 9, 2025, 07:56Mortality Risk in Thrombotic Thrombocytopenic Purpura․ Insights from Laboratory Biomarkers
-
Sep 9, 2025, 06:21Vincentius Liong on Nanorobot Swarms vs Blood Clots
-
Sep 9, 2025, 05:53Noel Hiney Highlights the Value of Blood Donation and Community Support
-
Sep 10, 2025, 08:20Flora Peyvandi on Caplacizumab: Which VWF Assays Truly Measure Treatment Effectiveness?
-
Sep 10, 2025, 03:36International Journal of Stroke: Rising Incidence of Stroke in Young Adults
-
Sep 9, 2025, 19:11John Fanikos Shares Greg Piazza's Presentation On The Results of The HI-Pro Trial
-
Sep 9, 2025, 08:15Taha Ahmed Highlights Rare Case: LV Fibroelastoma Mimicking Thrombus Leading to Takotsubo
-
Sep 9, 2025, 08:14JAMA Neurology: MRI Aneurysm Wall Enhancement Predicts Risk of Intracranial Aneurysm Growth or Rupture
-
Sep 9, 2025, 20:15Linking a Single Dominant Antibody to HIT: A Novel Study Led by Ishac Nazy, Donald Arnold, and John G. Kelton
-
Sep 8, 2025, 14:24Von Willebrand Factor as a Therapeutic Target․ From Development to Clinical Application
-
Sep 8, 2025, 02:35Reza Shojaei on the Real Worth of Hemoglobin Oxygen Carriers – HBOCs
-
Sep 7, 2025, 14:16Mary Kiige: Biological Hemoglobin Oxygen Carrier as a Lifesaving Oxygen Bridge
-
Sep 7, 2025, 14:13Breakthrough in Blood: Cécile Denis and INSERM Team Develop Nanobody Therapy for Type 1 VWD
-
Sep 9, 2025, 10:34James Douketis Receives the 2025 Distinguished Service Award in General Internal Medicine!
-
Sep 9, 2025, 08:07Hemophilia Federation of America Launches ‘Blood Brothers’ Podcast for Men With Bleeding Disorders
-
Sep 9, 2025, 04:57World Thrombosis Day 2025: Louise Bannon Invites Donations and Partnerships
-
Sep 8, 2025, 15:10Michael Makris on WHO’s Essential Medicines List Update: A Win for the Global Haemophilia Community
-
Sep 8, 2025, 14:26European Haemophilia Consortium Marks World PT Day: Physiotherapy Empowers People with Bleeding Disorders